Gem Pharmaceuticals (United States)

Recent papers from Gem Pharmaceuticals (United States)

1. A phase II clinical study of 13‐deoxy, 5‐iminodoxorubicin (GPX‐150) with metastatic and unresectable soft tissue sarcomaCancer Medicine · 2019
2. A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancerBritish Journal of Cancer · 2012
3. Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or LymphomaClinical Cancer Research · 2010
4. The Combination of a Histone Deacetylase Inhibitor with the Bcl-2 Homology Domain-3 Mimetic GX15-070 Has Synergistic Antileukemia Activity by Activating Both Apoptosis and AutophagyClinical Cancer Research · 2010
5. The Psychosocial Aspects of Complementary and Alternative MedicinePharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2000